JPRN-UMIN000041380招募中未知
The safety and efficacy of nintedanib for patients with progressive fibrosing interstitial lung disease in a real world setting-a prospective observational study - Nintedanib for PF-ILD in a real world setting
Department of Respiratory Medicine, Juntendo University Hospital0 个研究点目标入组 300 人开始时间: 2020年8月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Difficulty obtaining patients' consent (2) Severe heart disease (3) AST >=2*ULN, ALT >=2*ULN, or T-bil >=2*ULN (4) Pregnancy (5) Coexistence with pulmonary arterial hypertension, bronchial asthma, Malignant tumor, sarcoidosis, bronchiectasis, respiratory infection (6) A patient who already receive nintedanib or other anti-fibrotic agents (7) A patient with risk of fatal bleeding (8) Past history of thrombosis less than 3 months (9) A patient who started clinical trials less than 3 months (10) A patient improper to this clinical trial according to the decision of a principal investigator
研究者
相似试验
招募中
不适用
Efficacy and safety of nintedanib for progressive fibrosing interstitial diseases in single center cohort studyJPRN-UMIN000042254Japanese Red Cross Medical Center40
进行中（未招募）
1 期
Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseEPICUREHereditary Hemorrhagic TelangiectasiaMedDRA version: 20.1Level: LLTClassification code 10019887Term: Hereditary hemorrhagic telangiectasiaSystem Organ Class: 100000004850EUCTR2019-002593-31-FRHospices Civils de Lyon60
已完成
不适用
The safety and efficacy of Lenvatinib for patients with unresectable hepatocellular carcinoma on practical medicine after the approvalHepatocellular carcinomaJPRN-UMIN000034333ational Hospital Organization Kyoto Medical Center500
尚未招募
不适用
Efficacy and safety evaluation of nilotinib as primary treatment in newly diagnosed Philadelphia chromosome positive(Ph+) chronic myeloid leukemia(CML) patientsDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0000615Seoul National University Hospital114
招募中
不适用
Efficacy and Safety of Nintedanib in Idiopathic Pleuroparenchymal Fibroelastosis (Phase 2 trial)Idiopathic pleuroparenchymal fibroelastosisJPRN-UMIN000042946Department of Respiratory Medicine and Rheumatology Graduate School of Biomedical Sciences Tokushima University10